DexCom, Inc. (DXCM) Showcases Next-Gen CGM Features at EASD 2025

Core Insights - DexCom, Inc. is recognized as one of the best healthcare stocks to buy and hold for five years, primarily due to its leadership in continuous glucose monitoring (CGM) systems [1][2]. Company Overview - DexCom, Inc. (NASDAQ:DXCM) specializes in CGM systems, with its flagship G6 and G7 devices offering real-time glucose tracking and data sharing [2]. - The company showcased next-generation CGM features at EASD 2025, emphasizing its commitment to innovation in biosensing technology aimed at improving health outcomes and cost-effectiveness [2]. Financial Performance - In the second quarter of 2025, DexCom reported a revenue increase of 15.2% year-over-year, with earnings per share surpassing analyst expectations [3]. - Analysts maintain a moderate to strong buy consensus on DXCM, with price targets approaching $100, driven by robust demand for its CGM systems [3]. Recent Challenges - In September 2025, DexCom faced challenges due to allegations of unauthorized design changes in the G7 system, which were linked to severe safety risks, including hospitalizations and deaths [4]. - This controversy led to an 11.76% decline in stock price and initiated a class action investigation by Pomerantz LLP regarding potential securities fraud claims [4].